NCT06668025

MxA-Guided Antiviral Treatment in Respiratory Viral Infections

Application of Myxovirus Resistance Protein A in Antiviral Treatment Guidance of Respiratory Viral Infections

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot randomized controlled trial (RCT) will investigate the clinical impact of Myxovirus Resistance Protein A (MxA)-guided antiviral treatment versus standard treatment in patients with respiratory viral infections.

Detailed description

Effective antiviral treatment would shorten the time to symptom resolution, accelerate the cessation of viral shedding, and improve the prognosis of respiratory viral infections. However, the optimal timing for antiviral treatment remains undetermined, and the current lack of objective biomarkers for respiratory viral infections often leads to either prolonged or insufficient antiviral treatment. Thus, there is a need for strategies that incorporate novel diagnostics to guide antiviral treatment and provide more individualized therapy. Myxovirus resistance protein A (MxA), a novel marker of viral infection, may hold potential in guiding antiviral therapy. In this pilot randomized controlled clinical study, we aim to evaluate whether MxA-guided antiviral treatment, as compared to standard care, can reduce the recurrence rate of respiratory viral infections and improve clinical outcomes

Conditions

• Respiratory Viral Infections
• Influenza
• SARS CoV-2

Interventions

Type	Name	Description
OTHER	MxA tests	Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing. MxA measurements on Days 4, 7, and 10 will be performed only for patients still hospitalized on antiviral thearpy or at the attending physician's discretion.
OTHER	MxA feedback	MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.
OTHER	Follow-up at Day 30	A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.

Timeline

• Start date: 2024-12-12
• Primary completion: 2026-01-28
• Completion: 2026-02-12
• First posted: 2024-10-31
• Last updated: 2026-03-04

Locations

1 site across 1 country: China